Peer-reviewed veterinary case report
Preventing bladder bleeding from chemo in dogs with mesna
By Laberke, S et al.·Published in The Veterinary record·2014·Clinic of Small Animal Medicine, Germany·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Mesna and furosemide for prevention of cyclophosphamide-induced sterile haemorrhagic cystitis in dogs--a retrospective study.
- Species:
- dog
Plain-English summary
A group of dogs undergoing chemotherapy for lymphoma were monitored for a serious side effect called sterile hemorrhagic cystitis (SHC), which can cause painful urination and blood in the urine. The study compared two preventive treatments: mesna and furosemide. Dogs that received either mesna or furosemide had a much lower chance of developing SHC compared to those who did not receive any preventive treatment. This suggests that both mesna and furosemide are effective options to help protect dogs from this painful condition during chemotherapy.
People also search for: dog chemotherapy side effects · blood in urine dog treatment · mesna for dog cystitis · furosemide for dog cancer treatment
Abstract
Sterile haemorrhagic cystitis (SHC) is a possible side effect of cyclophosphamide which can severely impact quality of life. Mesna and diuresis are effective in human medicine to prevent SHC. The aim of the present study was to compare the efficacy of mesna versus diuresis with furosemide in preventing SHC in dogs treated with cyclophosphamide within a multidrug chemotherapy induction protocol for malignant lymphoma. Medical records of dogs treated at the Clinic of Small Animal Medicine, Munich, between 1997 and 2009 were analysed retrospectively. Of the 131 dogs included, 33 received no prophylaxis (group 1), 43 received mesna (group 2), and 55 received furosemide (group 3). Age, gender, breed, bodyweight, body surface area, dose and application method of cyclophosphamide, and the method of SHC prophylaxis were compared between dogs with and without SHC. Six dogs (4.6 per cent) developed SHC. The incidence of SHC in groups 1, 2 and 3 was 4/33 (12.1 per cent), 1/43 (2.3 per cent), and 1/55 (1.8 per cent), respectively. Dogs receiving either mesna or furosemide were significantly less likely to develop SHC (P=0.03). Otherwise no significant differences were found. In conclusion, this study demonstrates the efficacy and the medical indication of mesna and furosemide for prevention of cyclophosphamide-induced SHC.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/24463993/